<DOC>
	<DOCNO>NCT02901704</DOCNO>
	<brief_summary>The purpose Iberis-HTN trial evaluate safety effectiveness renal denervation subject primary hypertension use Iberis multielectrode renal denervation system</brief_summary>
	<brief_title>Renal Denervation Iberis MultiElectrode Renal Denervation System Patients With Primary Hypertension</brief_title>
	<detailed_description>The purpose evaluate 3-month outcome RDN treatment primary hypertension Chinese patients.In prospective , multi-center study , 216 Chinese patient primary hypertension would recruit undergo RDN Iberis Multielectrode denervation system . The primary effectiveness endpoint wasReduction average 24-hour ambulatory systolic blood pressue 3 month follow-up .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Age 18 65 year Primary Hypertension Stable medication regimen include 3 antihypertensive medication different class , include diuretic ( change minimum 4 week prior screen ) 1 ) Office SBP ≥150 ≤180 mmHg , DBP ≥90 , 2 ) average 24hour ambulatory systolic blood pressue and/or DBP ≥135 ≤170 mmHg Main renal artery ≥3 mm diameter ≥20 mm treatable length ( visual estimation ) Written informed consent Clinical Known secondary hypertension Type 1 diabetes mellitus Has implantable cardioverter defibrillator ( ICD ) pacemaker Myocardial infarction , unstable angina pectoris , syncope , cerebrovascular accident within 6 month screen period Has hemodynamically significant valvular heart disease Pregnant , nursing , plan pregnant Any serious medical condition may adversely affect safety participant study Currently enrol another investigational drug device trial 2.Angiographic Exclusion Criteria Renal artery stenosis ( ≥50 % ) renal artery aneurysm either renal artery History prior renal artery intervention include balloon angioplasty stenting Multiple renal artery main renal artery estimate supply &lt; 75 % kidney Main renal artery &lt; 3 mm diameter &lt; 20 mm treatable length ( visual estimation ) Renal artery abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>